NKGen Secures FDA Expanded Access For NK Cell Therapy In Neurodegenerative Diseases, Stock Down
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 21 2025
0mins
Should l Buy ?
Source: NASDAQ.COM
FDA Approval: NKGen Biotech has received FDA approval for an Intermediate-Size Expanded Access Program IND for its troculeucel candidate, allowing treatment of up to 20 patients with various neurodegenerative disorders, including early-stage Alzheimer's and Parkinson's disease.
Market Impact: Following the announcement, NKGN's stock is trading at $0.24, reflecting a decrease of 9.43 percent on the OTC Markets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
